^
Association details:
| Biomarker: | MET D1010Y |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Excerpt:
Treatment outcomes were available for eight previously unpublished METex14 cases treated with crizotinib. All eight patients in these cases experienced disease control, including four partial responses and two complete responses (five responses are ongoing), and two cases with stable disease (Table 3 and Fig. 2).
DOI:
https://doi.org/10.1016/j.jtho.2016.06.004
